Next earnings date: 1 Oct 2025
AngioDynamics, Inc. – NASDAQ:ANGO
AngioDynamics stock price today
$8.82
-0.08
-1.01%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
AngioDynamics stock price monthly change
+48.50%
month
AngioDynamics stock price quarterly change
+48.50%
quarter
AngioDynamics stock price yearly change
+10.82%
year
AngioDynamics key metrics
Market Cap | 355.34M |
Enterprise value | 397.40M |
P/E | -10.06 |
EV/Sales | 1.18 |
EV/EBITDA | -62.84 |
Price/Sales | 1.12 |
Price/Book | 0.94 |
PEG ratio | -0.58 |
EPS | -5.61 |
Revenue | 333.96M |
EBITDA | 6.76M |
Income | -224.95M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -11.13% |
Oper. margin | -10.98% |
Gross margin | 52.09% |
EBIT margin | -10.98% |
EBITDA margin | 2.02% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAngioDynamics stock price history
AngioDynamics stock forecast
AngioDynamics financial statements
| May 2022 | 86.99M | -6.26M | -7.2% |
|---|---|---|---|
| Feb 2023 | 80.71M | -9.48M | -11.75% |
| May 2023 | 91.07M | -21.46M | -23.57% |
| Feb 2024 | 75.18M | -187.73M | -249.71% |
| 2028 | 388.21M | 21.71M | 5.59% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2024-10-03 | -0.15 | -0.11 |
|---|
| Nov 2022 | 558207000 | 150.24M | 26.92% |
|---|---|---|---|
| Feb 2023 | 542849000 | 145.19M | 26.75% |
| May 2023 | 532637000 | 154.34M | 28.98% |
| Feb 2024 | 324842000 | 106.14M | 32.68% |
| May 2022 | 8.56M | -3.77M | 329K |
|---|---|---|---|
| Feb 2023 | 1.37M | -2.14M | 941K |
| May 2023 | 15.95M | -1.52M | -751K |
| Feb 2024 | -12.52M | 29.40M | 694K |
AngioDynamics alternative data
| Sep 2023 | 815 |
|---|---|
| Oct 2023 | 815 |
| Nov 2023 | 815 |
| Dec 2023 | 815 |
| Jan 2024 | 815 |
| Feb 2024 | 815 |
| Mar 2024 | 815 |
| Apr 2024 | 815 |
| May 2024 | 815 |
| Jun 2024 | 815 |
| Jul 2024 | 815 |
AngioDynamics other data
56.88%
-37.20%
of ANGO is owned by hedge funds
87
-57
22.47M
-14.67M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2024 | 10000 | 0 |
| Oct 2024 | 22568 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | NIGHAN WARREN JR officer: SVP Quality and Regula.. | Common Stock | 100 | $6.08 | $608 | ||
Purchase | TROWBRIDGE STEPHEN A officer: EVP and .. | Common Stock | 1,700 | $5.86 | $9,962 | ||
Purchase | NIGHAN WARREN JR officer: SVP Quality and Regula.. | Common Stock | 768 | $6.09 | $4,677 | ||
Purchase | CLEMMER JAMES C director, officer.. | Common Stock | 20,000 | $6.03 | $120,600 | ||
Option | PICCININI LAURA officer: SVP International | Common Stock | 4,439 | N/A | N/A | ||
Option | PICCININI LAURA officer: SVP International | Performance Right | 5,903 | N/A | N/A | ||
Option | CLEMMER JAMES C director, officer.. | Common Stock | 56,279 | N/A | N/A | ||
Option | CLEMMER JAMES C director, officer.. | Performance Right | 52,378 | N/A | N/A | ||
Option | NIGHAN WARREN JR officer: SVP Quality and Regula.. | Common Stock | 5,677 | N/A | N/A | ||
Option | NIGHAN WARREN JR officer: SVP Quality and Regula.. | Performance Right | 7,550 | N/A | N/A |
| Patent |
|---|
Application Filling date: 20 Apr 2022 Issue date: 11 Aug 2022 |
Application Filling date: 16 Dec 2021 Issue date: 7 Apr 2022 |
Grant Filling date: 8 Jan 2018 Issue date: 25 Jan 2022 |
Application Filling date: 14 Jun 2021 Issue date: 2 Dec 2021 |
Application SYSTEM AND METHOD FOR ABLATING A TISSUE SITE BY ELECTROPORATION WITH REAL-TIME MONITORING OF TREATMENT PROGRESS Filling date: 4 Jun 2021 Issue date: 25 Nov 2021 |
Grant Design: Implantable port Filling date: 5 Jan 2021 Issue date: 16 Nov 2021 |
Application Filling date: 13 Apr 2021 Issue date: 14 Oct 2021 |
Grant Filling date: 9 Mar 2021 Issue date: 21 Sep 2021 |
Application Filling date: 8 Feb 2021 Issue date: 9 Sep 2021 |
Application Filling date: 1 Apr 2021 Issue date: 22 Jul 2021 |
| Quarter | Transcript |
|---|---|
| Q3 2024 4 Apr 2024 | Q3 2024 Earnings Call Transcript |
| Q2 2024 5 Jan 2024 | Q2 2024 Earnings Call Transcript |
| Q1 2024 4 Oct 2023 | Q1 2024 Earnings Call Transcript |
| Q4 2023 12 Jul 2023 | Q4 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. James C. Clemmer (1964) Chief Executive Officer, Pres & Director | $1,910,000 |
| Mr. Stephen A. Trowbridge (1974) Executive Vice President & Chief Financial Officer | $812,990 |
Mr. David D. Helsel (1964) Senior Vice President of Global Operations and R&D | $664,290 |
Mr. Warren G. Nighan (1969) Senior Vice President of Quality & Regulatory Affairs | $622,110 |
| Mr. Chad T. Campbell (1971) Senior Vice President & GM of Vascular Access Global Bus. Unit | $589,750 |
A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
AngioDynamics: Enormous Effort Required In Fiscal '24 To Reverse The Equity Picture
Merit Medical: Reasonably-Priced Execution, With M&A Upside
AngioDynamics: Growth Is Encouraging, But Margins Still A Work In Progress
Penumbra A Little Beaten Down Despite Strong Growth Opportunities
Red Hot Inflation: Healthcare Stocks You Can Buy
-
What's the price of AngioDynamics stock today?
One share of AngioDynamics stock can currently be purchased for approximately $8.82.
-
When is AngioDynamics's next earnings date?
AngioDynamics, Inc. is estimated to report earnings on Wednesday, 1 Oct 2025.
-
Does AngioDynamics pay dividends?
No, AngioDynamics does not pay dividends.
-
How much money does AngioDynamics make?
AngioDynamics has a market capitalization of 355.34M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 10.28% to 303.91M US dollars. AngioDynamics made a loss 184.35M US dollars in net income (profit) last year or -$0.11 on an earnings per share basis.
-
What is AngioDynamics's stock symbol?
AngioDynamics, Inc. is traded on the NASDAQ under the ticker symbol "ANGO".
-
What is AngioDynamics's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of AngioDynamics?
Shares of AngioDynamics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are AngioDynamics's key executives?
AngioDynamics's management team includes the following people:
- Mr. James C. Clemmer Chief Executive Officer, Pres & Director(age: 61, pay: $1,910,000)
- Mr. Stephen A. Trowbridge Executive Vice President & Chief Financial Officer(age: 51, pay: $812,990)
- Mr. David D. Helsel Senior Vice President of Global Operations and R&D(age: 61, pay: $664,290)
- Mr. Warren G. Nighan Senior Vice President of Quality & Regulatory Affairs(age: 56, pay: $622,110)
- Mr. Chad T. Campbell Senior Vice President & GM of Vascular Access Global Bus. Unit(age: 54, pay: $589,750)
-
How many employees does AngioDynamics have?
As Jul 2024, AngioDynamics employs 815 workers.
-
When AngioDynamics went public?
AngioDynamics, Inc. is publicly traded company for more then 21 years since IPO on 1 Jun 2004.
-
What is AngioDynamics's official website?
The official website for AngioDynamics is angiodynamics.com.
-
Where are AngioDynamics's headquarters?
AngioDynamics is headquartered at 14 Plaza Drive, Latham, NY.
-
How can i contact AngioDynamics?
AngioDynamics's mailing address is 14 Plaza Drive, Latham, NY and company can be reached via phone at +51 87 951400.
AngioDynamics company profile:
AngioDynamics, Inc.
angiodynamics.comExchange:
NASDAQ
Full time employees:
748
Industry:
Medical - Instruments & Supplies
Sector:
Healthcare
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
14 Plaza Drive
Latham, NY 12110
Latham, NY 12110
CIK: 0001275187
ISIN: US03475V1017
CUSIP: 03475V101
